Yong-Moon Park
Concepts (390)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 48 | 2026 | 568 | 6.740 |
Why?
| | Obesity | 40 | 2026 | 1188 | 5.520 |
Why?
| | Republic of Korea | 72 | 2026 | 95 | 4.570 |
Why?
| | Nutrition Surveys | 38 | 2023 | 117 | 4.230 |
Why?
| | Breast Neoplasms | 17 | 2026 | 1206 | 4.100 |
Why?
| | Diet, Mediterranean | 8 | 2023 | 10 | 3.900 |
Why?
| | Risk Factors | 90 | 2026 | 3950 | 3.240 |
Why?
| | Cardiovascular Diseases | 20 | 2025 | 494 | 3.090 |
Why?
| | Insulin Resistance | 17 | 2018 | 279 | 3.070 |
Why?
| | Hypertension | 19 | 2025 | 568 | 2.910 |
Why?
| | Blood Glucose | 25 | 2025 | 476 | 2.880 |
Why?
| | Body Mass Index | 38 | 2025 | 700 | 2.600 |
Why?
| | Middle Aged | 121 | 2026 | 13091 | 2.510 |
Why?
| | Female | 143 | 2026 | 28214 | 2.210 |
Why?
| | Adult | 107 | 2026 | 14168 | 2.120 |
Why?
| | Aged | 91 | 2026 | 10200 | 1.970 |
Why?
| | Humans | 165 | 2026 | 52546 | 1.840 |
Why?
| | Diet | 11 | 2023 | 600 | 1.760 |
Why?
| | Diabetes Mellitus | 12 | 2025 | 318 | 1.760 |
Why?
| | Proportional Hazards Models | 25 | 2026 | 444 | 1.530 |
Why?
| | Male | 111 | 2025 | 26808 | 1.530 |
Why?
| | Triglycerides | 12 | 2020 | 168 | 1.530 |
Why?
| | Overweight | 8 | 2019 | 230 | 1.520 |
Why?
| | Postmenopause | 9 | 2026 | 83 | 1.480 |
Why?
| | Metformin | 4 | 2021 | 81 | 1.470 |
Why?
| | Prospective Studies | 29 | 2023 | 2450 | 1.460 |
Why?
| | Inflammation | 4 | 2022 | 643 | 1.450 |
Why?
| | Health Surveys | 9 | 2020 | 238 | 1.370 |
Why?
| | Siblings | 3 | 2021 | 34 | 1.320 |
Why?
| | Incidence | 29 | 2025 | 1077 | 1.290 |
Why?
| | Blood Pressure | 14 | 2025 | 537 | 1.260 |
Why?
| | Cross-Sectional Studies | 24 | 2023 | 1680 | 1.250 |
Why?
| | Periodontitis | 6 | 2021 | 11 | 1.200 |
Why?
| | Exercise | 7 | 2024 | 552 | 1.200 |
Why?
| | Prevalence | 25 | 2025 | 1017 | 1.170 |
Why?
| | Cohort Studies | 37 | 2026 | 1552 | 1.160 |
Why?
| | Dementia | 3 | 2026 | 135 | 1.140 |
Why?
| | F2-Isoprostanes | 4 | 2023 | 8 | 1.140 |
Why?
| | Hypoglycemia | 8 | 2022 | 60 | 1.130 |
Why?
| | Income | 3 | 2024 | 103 | 1.050 |
Why?
| | Neoplasms | 7 | 2025 | 1305 | 1.010 |
Why?
| | Aging | 6 | 2022 | 709 | 1.000 |
Why?
| | Feeding Behavior | 5 | 2022 | 196 | 0.990 |
Why?
| | Waist Circumference | 11 | 2020 | 21 | 0.940 |
Why?
| | Oxidative Stress | 5 | 2023 | 809 | 0.910 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2025 | 46 | 0.890 |
Why?
| | Follow-Up Studies | 26 | 2025 | 2290 | 0.880 |
Why?
| | Mammography | 1 | 2025 | 97 | 0.870 |
Why?
| | Circadian Rhythm | 1 | 2024 | 91 | 0.860 |
Why?
| | Diabetic Retinopathy | 6 | 2016 | 44 | 0.860 |
Why?
| | Stroke | 10 | 2024 | 516 | 0.850 |
Why?
| | Esophageal Neoplasms | 2 | 2022 | 111 | 0.840 |
Why?
| | Young Adult | 22 | 2024 | 4329 | 0.840 |
Why?
| | Cataract | 2 | 2015 | 45 | 0.830 |
Why?
| | Atrial Fibrillation | 2 | 2024 | 201 | 0.820 |
Why?
| | Premenopause | 9 | 2026 | 28 | 0.800 |
Why?
| | Body Weight | 6 | 2019 | 526 | 0.800 |
Why?
| | Aged, 80 and over | 18 | 2024 | 3414 | 0.790 |
Why?
| | Diabetes, Gestational | 3 | 2022 | 52 | 0.780 |
Why?
| | Diabetic Angiopathies | 5 | 2018 | 24 | 0.770 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 2 | 2014 | 179 | 0.770 |
Why?
| | Isoprostanes | 1 | 2022 | 2 | 0.750 |
Why?
| | Cholesterol | 8 | 2021 | 161 | 0.740 |
Why?
| | United States | 20 | 2023 | 5225 | 0.740 |
Why?
| | Risk Assessment | 5 | 2019 | 1348 | 0.700 |
Why?
| | Age Factors | 8 | 2020 | 1131 | 0.690 |
Why?
| | Cholesterol, HDL | 9 | 2021 | 38 | 0.690 |
Why?
| | Glaucoma, Open-Angle | 2 | 2020 | 24 | 0.680 |
Why?
| | Coronary Artery Disease | 4 | 2025 | 320 | 0.660 |
Why?
| | Intraocular Pressure | 4 | 2020 | 59 | 0.640 |
Why?
| | Odds Ratio | 9 | 2018 | 565 | 0.630 |
Why?
| | Phenotype | 8 | 2026 | 800 | 0.630 |
Why?
| | Insulin | 8 | 2018 | 485 | 0.630 |
Why?
| | Menopause | 2 | 2026 | 38 | 0.620 |
Why?
| | Myocardial Infarction | 6 | 2024 | 448 | 0.620 |
Why?
| | Metabolic Diseases | 3 | 2017 | 47 | 0.590 |
Why?
| | Cause of Death | 7 | 2025 | 163 | 0.590 |
Why?
| | Adenocarcinoma | 1 | 2022 | 402 | 0.590 |
Why?
| | Acidosis | 1 | 2018 | 41 | 0.590 |
Why?
| | Fasting | 6 | 2020 | 75 | 0.570 |
Why?
| | Hypoglycemic Agents | 6 | 2021 | 217 | 0.570 |
Why?
| | Physical Fitness | 2 | 2015 | 57 | 0.560 |
Why?
| | Plaque, Atherosclerotic | 1 | 2018 | 44 | 0.550 |
Why?
| | Diabetic Neuropathies | 5 | 2018 | 56 | 0.540 |
Why?
| | Retrospective Studies | 20 | 2026 | 6644 | 0.520 |
Why?
| | Hypertriglyceridemia | 2 | 2014 | 18 | 0.520 |
Why?
| | Glucose Intolerance | 3 | 2025 | 28 | 0.520 |
Why?
| | Alanine Transaminase | 2 | 2014 | 120 | 0.510 |
Why?
| | Breast Feeding | 1 | 2018 | 196 | 0.510 |
Why?
| | Prognosis | 15 | 2024 | 2113 | 0.510 |
Why?
| | Sex Factors | 10 | 2017 | 731 | 0.500 |
Why?
| | Sleep | 4 | 2024 | 186 | 0.490 |
Why?
| | Obesity, Abdominal | 5 | 2023 | 20 | 0.480 |
Why?
| | Colorectal Neoplasms | 4 | 2024 | 295 | 0.470 |
Why?
| | Nutrition Assessment | 4 | 2021 | 68 | 0.470 |
Why?
| | Ideal Body Weight | 1 | 2015 | 6 | 0.470 |
Why?
| | Lipids | 2 | 2015 | 160 | 0.460 |
Why?
| | Muscles | 1 | 2015 | 108 | 0.460 |
Why?
| | Diabetes Complications | 2 | 2015 | 125 | 0.460 |
Why?
| | Lipoproteins | 1 | 2015 | 41 | 0.460 |
Why?
| | Kidney Failure, Chronic | 3 | 2025 | 215 | 0.460 |
Why?
| | Antihypertensive Agents | 3 | 2016 | 131 | 0.450 |
Why?
| | Zinc | 1 | 2015 | 56 | 0.450 |
Why?
| | Autonomic Nervous System | 4 | 2018 | 60 | 0.450 |
Why?
| | Energy Metabolism | 1 | 2017 | 312 | 0.440 |
Why?
| | Heart Rate | 7 | 2018 | 318 | 0.420 |
Why?
| | Intellectual Disability | 2 | 2024 | 128 | 0.410 |
Why?
| | Body Composition | 1 | 2015 | 341 | 0.400 |
Why?
| | Bipolar Disorder | 1 | 2014 | 199 | 0.390 |
Why?
| | Sarcopenia | 1 | 2014 | 98 | 0.390 |
Why?
| | Depressive Disorder, Major | 1 | 2014 | 148 | 0.390 |
Why?
| | Ferritins | 1 | 2012 | 36 | 0.380 |
Why?
| | Lipoprotein(a) | 3 | 2016 | 6 | 0.370 |
Why?
| | Comorbidity | 5 | 2018 | 631 | 0.370 |
Why?
| | Dinoprost | 3 | 2022 | 7 | 0.360 |
Why?
| | Osteoarthritis, Knee | 2 | 2023 | 97 | 0.360 |
Why?
| | Socioeconomic Factors | 4 | 2018 | 606 | 0.360 |
Why?
| | Adipose Tissue | 1 | 2013 | 205 | 0.350 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2012 | 511 | 0.350 |
Why?
| | Databases, Factual | 6 | 2024 | 715 | 0.340 |
Why?
| | Percutaneous Coronary Intervention | 2 | 2025 | 328 | 0.340 |
Why?
| | Alcohol Drinking | 6 | 2021 | 236 | 0.310 |
Why?
| | Cardiovascular System | 3 | 2018 | 55 | 0.310 |
Why?
| | Meat | 2 | 2019 | 61 | 0.300 |
Why?
| | Energy Intake | 3 | 2022 | 185 | 0.300 |
Why?
| | Sex Distribution | 5 | 2015 | 138 | 0.290 |
Why?
| | Toothbrushing | 2 | 2021 | 4 | 0.280 |
Why?
| | Medicaid | 4 | 2014 | 264 | 0.280 |
Why?
| | Case-Control Studies | 6 | 2025 | 1198 | 0.280 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2015 | 203 | 0.280 |
Why?
| | National Health Programs | 2 | 2024 | 18 | 0.270 |
Why?
| | Time Factors | 10 | 2020 | 2990 | 0.270 |
Why?
| | Korea | 5 | 2023 | 10 | 0.260 |
Why?
| | Brain Ischemia | 2 | 2018 | 162 | 0.240 |
Why?
| | Rural Population | 6 | 2025 | 573 | 0.240 |
Why?
| | Hypercholesterolemia | 2 | 2017 | 39 | 0.240 |
Why?
| | Reproduction | 1 | 2026 | 65 | 0.240 |
Why?
| | Diabetic Cardiomyopathies | 2 | 2017 | 4 | 0.240 |
Why?
| | ROC Curve | 4 | 2014 | 253 | 0.230 |
Why?
| | Dietary Fats | 2 | 2018 | 133 | 0.230 |
Why?
| | Antibodies, Bacterial | 3 | 2019 | 30 | 0.230 |
Why?
| | Time-to-Treatment | 1 | 2026 | 79 | 0.230 |
Why?
| | Educational Status | 3 | 2015 | 227 | 0.230 |
Why?
| | Weight Gain | 2 | 2025 | 244 | 0.220 |
Why?
| | Vitamin B 12 Deficiency | 2 | 2014 | 9 | 0.220 |
Why?
| | Lighting | 1 | 2024 | 5 | 0.220 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2025 | 112 | 0.220 |
Why?
| | Autonomic Nervous System Diseases | 2 | 2016 | 13 | 0.220 |
Why?
| | Myopia | 2 | 2014 | 9 | 0.220 |
Why?
| | Light | 1 | 2024 | 51 | 0.220 |
Why?
| | Healthcare Disparities | 2 | 2026 | 301 | 0.220 |
Why?
| | Poverty Areas | 1 | 2024 | 43 | 0.220 |
Why?
| | Logistic Models | 3 | 2018 | 932 | 0.210 |
Why?
| | Neoplasm Invasiveness | 1 | 2025 | 277 | 0.210 |
Why?
| | Air Pollutants | 1 | 2025 | 75 | 0.210 |
Why?
| | Sex Characteristics | 3 | 2016 | 198 | 0.210 |
Why?
| | Anthracyclines | 1 | 2024 | 31 | 0.210 |
Why?
| | Adolescent | 7 | 2023 | 6713 | 0.200 |
Why?
| | Up-Regulation | 3 | 2016 | 462 | 0.200 |
Why?
| | Receptors, Estrogen | 2 | 2021 | 131 | 0.200 |
Why?
| | Insurance Coverage | 1 | 2024 | 115 | 0.200 |
Why?
| | Early Detection of Cancer | 1 | 2025 | 184 | 0.200 |
Why?
| | Health Status | 2 | 2015 | 299 | 0.200 |
Why?
| | Environmental Exposure | 1 | 2025 | 216 | 0.200 |
Why?
| | Cooking | 2 | 2019 | 16 | 0.200 |
Why?
| | Survivors | 1 | 2024 | 118 | 0.200 |
Why?
| | Risk | 3 | 2019 | 313 | 0.200 |
Why?
| | Down-Regulation | 2 | 2015 | 344 | 0.200 |
Why?
| | Lutein | 1 | 2022 | 4 | 0.190 |
Why?
| | beta Carotene | 1 | 2022 | 9 | 0.190 |
Why?
| | Carotenoids | 1 | 2022 | 24 | 0.190 |
Why?
| | Health Status Disparities | 1 | 2025 | 217 | 0.190 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2022 | 22 | 0.180 |
Why?
| | Hyperglycemia | 2 | 2019 | 89 | 0.180 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2022 | 70 | 0.180 |
Why?
| | Laryngeal Neoplasms | 1 | 2022 | 44 | 0.180 |
Why?
| | Registries | 4 | 2026 | 633 | 0.180 |
Why?
| | Health Services Accessibility | 1 | 2026 | 439 | 0.180 |
Why?
| | Lung | 1 | 2025 | 500 | 0.180 |
Why?
| | Plant Proteins | 1 | 2022 | 70 | 0.180 |
Why?
| | Periodontal Index | 3 | 2017 | 6 | 0.170 |
Why?
| | Tuberculosis | 1 | 2022 | 152 | 0.170 |
Why?
| | Child | 6 | 2018 | 7194 | 0.170 |
Why?
| | Reference Values | 3 | 2016 | 313 | 0.170 |
Why?
| | Glucose | 2 | 2020 | 359 | 0.170 |
Why?
| | Cardiac Surgical Procedures | 2 | 2013 | 325 | 0.160 |
Why?
| | Neoplasm Staging | 2 | 2025 | 766 | 0.160 |
Why?
| | Survival Rate | 3 | 2020 | 949 | 0.160 |
Why?
| | Anthropometry | 2 | 2017 | 101 | 0.160 |
Why?
| | Waist-Hip Ratio | 2 | 2017 | 9 | 0.160 |
Why?
| | Depression | 1 | 2024 | 604 | 0.150 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2019 | 41 | 0.150 |
Why?
| | Influenza, Human | 1 | 2020 | 85 | 0.150 |
Why?
| | Breakfast | 1 | 2019 | 19 | 0.150 |
Why?
| | Arkansas | 4 | 2026 | 2026 | 0.150 |
Why?
| | Anti-Mullerian Hormone | 1 | 2018 | 4 | 0.150 |
Why?
| | Smoking | 4 | 2017 | 517 | 0.150 |
Why?
| | Smoking Cessation | 1 | 2022 | 315 | 0.150 |
Why?
| | Albuminuria | 3 | 2016 | 49 | 0.150 |
Why?
| | Parkinson Disease | 1 | 2021 | 155 | 0.150 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 179 | 0.150 |
Why?
| | Diabetic Nephropathies | 2 | 2016 | 61 | 0.150 |
Why?
| | Vegetables | 1 | 2018 | 67 | 0.140 |
Why?
| | Epigenesis, Genetic | 1 | 2022 | 403 | 0.140 |
Why?
| | Mouth | 1 | 2018 | 33 | 0.140 |
Why?
| | Glycemic Index | 1 | 2018 | 3 | 0.140 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2020 | 201 | 0.140 |
Why?
| | South Carolina | 2 | 2014 | 23 | 0.140 |
Why?
| | Fruit | 1 | 2018 | 129 | 0.140 |
Why?
| | Severity of Illness Index | 5 | 2020 | 1038 | 0.140 |
Why?
| | Cluster Analysis | 1 | 2018 | 237 | 0.140 |
Why?
| | Dental Caries | 1 | 2017 | 9 | 0.140 |
Why?
| | Heart Defects, Congenital | 2 | 2013 | 615 | 0.140 |
Why?
| | Periodontal Diseases | 1 | 2017 | 12 | 0.130 |
Why?
| | Membrane Transport Modulators | 1 | 2017 | 6 | 0.130 |
Why?
| | Longitudinal Studies | 5 | 2022 | 746 | 0.130 |
Why?
| | Alzheimer Disease | 1 | 2021 | 331 | 0.130 |
Why?
| | Tonometry, Ocular | 1 | 2016 | 6 | 0.130 |
Why?
| | Psoriasis | 1 | 2017 | 29 | 0.130 |
Why?
| | Liver Neoplasms | 1 | 2020 | 333 | 0.130 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2017 | 28 | 0.130 |
Why?
| | Obesity, Morbid | 1 | 2018 | 89 | 0.130 |
Why?
| | Stomach Neoplasms | 1 | 2020 | 194 | 0.130 |
Why?
| | Age Distribution | 2 | 2015 | 175 | 0.130 |
Why?
| | Heart | 2 | 2016 | 360 | 0.120 |
Why?
| | Pregnancy | 3 | 2022 | 2671 | 0.120 |
Why?
| | C-Reactive Protein | 1 | 2016 | 152 | 0.120 |
Why?
| | Prediabetic State | 1 | 2015 | 22 | 0.120 |
Why?
| | Predictive Value of Tests | 5 | 2017 | 946 | 0.120 |
Why?
| | Blepharoptosis | 1 | 2015 | 12 | 0.120 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 883 | 0.120 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 106 | 0.120 |
Why?
| | Laminectomy | 1 | 2015 | 8 | 0.120 |
Why?
| | Rural Health | 1 | 2015 | 88 | 0.120 |
Why?
| | Diskectomy | 1 | 2015 | 11 | 0.110 |
Why?
| | Preoperative Period | 1 | 2015 | 47 | 0.110 |
Why?
| | Diabetic Foot | 1 | 2016 | 76 | 0.110 |
Why?
| | Texas | 1 | 2015 | 141 | 0.110 |
Why?
| | Adrenergic Uptake Inhibitors | 1 | 2014 | 14 | 0.110 |
Why?
| | Patient Compliance | 1 | 2016 | 229 | 0.110 |
Why?
| | Conduct Disorder | 1 | 2014 | 9 | 0.110 |
Why?
| | beta 2-Microglobulin | 1 | 2014 | 39 | 0.110 |
Why?
| | Glaucoma | 1 | 2014 | 34 | 0.110 |
Why?
| | Drug Combinations | 1 | 2014 | 134 | 0.110 |
Why?
| | Social Class | 1 | 2015 | 95 | 0.110 |
Why?
| | Food Supply | 1 | 2015 | 92 | 0.110 |
Why?
| | Anesthesia, General | 1 | 2015 | 97 | 0.110 |
Why?
| | Forecasting | 1 | 2015 | 154 | 0.110 |
Why?
| | Linear Models | 1 | 2015 | 291 | 0.110 |
Why?
| | Health Status Indicators | 1 | 2014 | 80 | 0.110 |
Why?
| | Anxiety Disorders | 1 | 2014 | 130 | 0.110 |
Why?
| | Metabolome | 1 | 2015 | 103 | 0.110 |
Why?
| | Exercise Test | 1 | 2014 | 144 | 0.110 |
Why?
| | Vitamin D Deficiency | 1 | 2014 | 46 | 0.100 |
Why?
| | Analysis of Variance | 1 | 2015 | 557 | 0.100 |
Why?
| | Vitamin D | 1 | 2014 | 91 | 0.100 |
Why?
| | Metabolomics | 1 | 2015 | 151 | 0.100 |
Why?
| | Organ Size | 1 | 2014 | 231 | 0.100 |
Why?
| | Asthma | 1 | 2017 | 316 | 0.100 |
Why?
| | Ibuprofen | 1 | 2013 | 24 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2015 | 336 | 0.100 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2013 | 6 | 0.100 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2013 | 81 | 0.100 |
Why?
| | Tachycardia, Supraventricular | 1 | 2013 | 37 | 0.100 |
Why?
| | Heart Septal Defects, Atrial | 1 | 2013 | 44 | 0.100 |
Why?
| | Ductus Arteriosus, Patent | 1 | 2013 | 40 | 0.100 |
Why?
| | Voluntary Health Agencies | 1 | 2012 | 4 | 0.100 |
Why?
| | International Agencies | 1 | 2012 | 15 | 0.100 |
Why?
| | Leukocyte Count | 1 | 2013 | 73 | 0.100 |
Why?
| | Adiponectin | 1 | 2013 | 46 | 0.100 |
Why?
| | Cardiovascular Agents | 1 | 2013 | 65 | 0.100 |
Why?
| | Absorptiometry, Photon | 1 | 2013 | 162 | 0.100 |
Why?
| | Central Nervous System Stimulants | 1 | 2014 | 199 | 0.100 |
Why?
| | Anxiety | 1 | 2015 | 301 | 0.090 |
Why?
| | Fatty Acids | 1 | 2013 | 151 | 0.090 |
Why?
| | Awareness | 1 | 2012 | 26 | 0.090 |
Why?
| | Multivariate Analysis | 3 | 2020 | 602 | 0.090 |
Why?
| | Catheter Ablation | 1 | 2013 | 125 | 0.090 |
Why?
| | Disease Management | 1 | 2013 | 186 | 0.090 |
Why?
| | Lipoproteins, LDL | 1 | 2013 | 171 | 0.090 |
Why?
| | Needs Assessment | 1 | 2012 | 139 | 0.090 |
Why?
| | Bone Morphogenetic Protein 4 | 1 | 2010 | 8 | 0.090 |
Why?
| | Diet Surveys | 2 | 2022 | 34 | 0.080 |
Why?
| | Kidney | 1 | 2015 | 722 | 0.080 |
Why?
| | Quercetin | 1 | 2009 | 18 | 0.080 |
Why?
| | Glutamate-Cysteine Ligase | 1 | 2009 | 21 | 0.080 |
Why?
| | Insulin-Secreting Cells | 1 | 2009 | 23 | 0.080 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2009 | 43 | 0.080 |
Why?
| | Early Growth Response Protein 1 | 1 | 2009 | 34 | 0.080 |
Why?
| | Puerto Rico | 2 | 2019 | 17 | 0.080 |
Why?
| | Actinomyces | 2 | 2019 | 12 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2012 | 498 | 0.080 |
Why?
| | Colonoscopy | 1 | 2009 | 107 | 0.070 |
Why?
| | Adenoma | 1 | 2009 | 113 | 0.070 |
Why?
| | Muscle, Skeletal | 1 | 2014 | 809 | 0.070 |
Why?
| | Antioxidants | 1 | 2009 | 257 | 0.070 |
Why?
| | Valsalva Maneuver | 3 | 2013 | 10 | 0.060 |
Why?
| | Life Style | 2 | 2022 | 146 | 0.060 |
Why?
| | Parity | 1 | 2026 | 53 | 0.060 |
Why?
| | Posture | 3 | 2013 | 66 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 483 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 638 | 0.060 |
Why?
| | Forced Expiratory Volume | 1 | 2025 | 52 | 0.060 |
Why?
| | Respiratory Function Tests | 1 | 2025 | 90 | 0.060 |
Why?
| | Spirometry | 1 | 2025 | 33 | 0.060 |
Why?
| | Cholesterol, LDL | 2 | 2016 | 43 | 0.060 |
Why?
| | Glomerular Filtration Rate | 2 | 2015 | 129 | 0.060 |
Why?
| | Mastectomy | 1 | 2026 | 144 | 0.060 |
Why?
| | Vitamin B 12 | 2 | 2014 | 27 | 0.050 |
Why?
| | Air Pollution | 1 | 2025 | 49 | 0.050 |
Why?
| | Patient Education as Topic | 1 | 2007 | 322 | 0.050 |
Why?
| | Folic Acid | 2 | 2014 | 136 | 0.050 |
Why?
| | Iatrogenic Disease | 1 | 2023 | 26 | 0.050 |
Why?
| | Poverty | 1 | 2024 | 220 | 0.050 |
Why?
| | Polysomnography | 1 | 2022 | 72 | 0.050 |
Why?
| | Diet, Vegetarian | 1 | 2022 | 6 | 0.050 |
Why?
| | Thinness | 1 | 2022 | 44 | 0.050 |
Why?
| | Longevity | 1 | 2022 | 86 | 0.040 |
Why?
| | Disease Progression | 2 | 2018 | 872 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 96 | 0.040 |
Why?
| | Mortality | 1 | 2021 | 105 | 0.040 |
Why?
| | Regression Analysis | 2 | 2013 | 401 | 0.040 |
Why?
| | Echocardiography | 2 | 2013 | 415 | 0.040 |
Why?
| | Fatty Liver | 1 | 2021 | 142 | 0.040 |
Why?
| | Poultry | 1 | 2019 | 29 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2023 | 1223 | 0.040 |
Why?
| | Receptors, Progesterone | 1 | 2019 | 66 | 0.040 |
Why?
| | Receptor, erbB-2 | 1 | 2019 | 79 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2019 | 195 | 0.040 |
Why?
| | Reflex | 1 | 2018 | 29 | 0.040 |
Why?
| | Animals | 3 | 2022 | 13464 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2018 | 18 | 0.040 |
Why?
| | Biometry | 1 | 2017 | 21 | 0.030 |
Why?
| | Vaccination | 1 | 2020 | 299 | 0.030 |
Why?
| | DNA Methylation | 1 | 2022 | 583 | 0.030 |
Why?
| | Oral Hygiene | 1 | 2017 | 5 | 0.030 |
Why?
| | Dietary Carbohydrates | 1 | 2018 | 90 | 0.030 |
Why?
| | Piperidones | 1 | 2017 | 7 | 0.030 |
Why?
| | Sodium-Glucose Transporter 2 | 1 | 2017 | 19 | 0.030 |
Why?
| | Glucosides | 1 | 2017 | 24 | 0.030 |
Why?
| | Sleep Apnea Syndromes | 1 | 2017 | 32 | 0.030 |
Why?
| | Hemodynamics | 1 | 2018 | 265 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 671 | 0.030 |
Why?
| | Hyperlipidemias | 1 | 2017 | 52 | 0.030 |
Why?
| | Exhalation | 1 | 2016 | 21 | 0.030 |
Why?
| | Benzhydryl Compounds | 1 | 2017 | 69 | 0.030 |
Why?
| | Dyslipidemias | 1 | 2016 | 42 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2016 | 61 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2016 | 294 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 399 | 0.030 |
Why?
| | Pyrimidines | 1 | 2017 | 199 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 58 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2015 | 53 | 0.030 |
Why?
| | Liver | 1 | 2021 | 1155 | 0.030 |
Why?
| | Intervertebral Disc Displacement | 1 | 2015 | 13 | 0.030 |
Why?
| | Proteinuria | 1 | 2015 | 41 | 0.030 |
Why?
| | Spinal Stenosis | 1 | 2015 | 12 | 0.030 |
Why?
| | Sulfonylurea Compounds | 1 | 2014 | 6 | 0.030 |
Why?
| | Recurrence | 1 | 2016 | 683 | 0.030 |
Why?
| | Infant | 2 | 2013 | 3691 | 0.030 |
Why?
| | Eating | 1 | 2015 | 159 | 0.030 |
Why?
| | Macular Edema | 1 | 2015 | 29 | 0.030 |
Why?
| | Immunoassay | 1 | 2014 | 23 | 0.030 |
Why?
| | Child, Preschool | 2 | 2013 | 4034 | 0.030 |
Why?
| | Refraction, Ocular | 1 | 2014 | 7 | 0.030 |
Why?
| | Population Surveillance | 1 | 2015 | 165 | 0.030 |
Why?
| | Area Under Curve | 1 | 2014 | 183 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 2015 | 102 | 0.030 |
Why?
| | Patients | 1 | 2014 | 51 | 0.030 |
Why?
| | Chemical Phenomena | 1 | 2013 | 17 | 0.030 |
Why?
| | Taurine | 1 | 2013 | 18 | 0.030 |
Why?
| | Particle Size | 1 | 2013 | 78 | 0.020 |
Why?
| | Progesterone | 1 | 2013 | 58 | 0.020 |
Why?
| | Brain | 1 | 2021 | 1322 | 0.020 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 123 | 0.020 |
Why?
| | Atherosclerosis | 1 | 2014 | 225 | 0.020 |
Why?
| | Lipoproteins, HDL | 1 | 2011 | 16 | 0.020 |
Why?
| | Sp1 Transcription Factor | 1 | 2009 | 20 | 0.020 |
Why?
| | Diastole | 1 | 2010 | 68 | 0.020 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2009 | 63 | 0.020 |
Why?
| | Systole | 1 | 2010 | 74 | 0.020 |
Why?
| | Adiposity | 1 | 2010 | 143 | 0.020 |
Why?
| | Colonic Polyps | 1 | 2009 | 39 | 0.020 |
Why?
| | Creatinine | 1 | 2008 | 159 | 0.020 |
Why?
| | Time | 1 | 2007 | 29 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2009 | 1139 | 0.020 |
Why?
| | Self Care | 1 | 2007 | 137 | 0.010 |
Why?
| | Rats | 1 | 2009 | 3182 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2013 | 5475 | 0.010 |
Why?
| | Hospitalization | 1 | 2007 | 749 | 0.010 |
Why?
|
|
Park's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|